Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
A new malaria vaccine achieves an unparalleled 89% efficacy by targeting late-liver-stage antigens, unlocking new horizons in the fight against global disease. Study: Safety and Efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results